Myelodysplastic Syndrome (MDS)/ CMML

IRB# 11076
Phase I
with
LOR-253

IRB# 15619
Phase 1/2
Vadastuximab
Talirine (SGN-CD33A) plus
Standard of
care chemo in
intermediate
to high risk
MDS

IRB# 11076
Non Treatment
National MDS
Study (ECOG/ACRIN)

IRB# 15977
Relapsed/
Refractory

IRB# 16142
Ph1 Oral
AG-120
treatment

IRB# 15993
Relapsed/
Refractory
(MDS)

IRB# 15953
Phase 2
treatment
with SY-1425, a
selective
Retinoic
Acid
Receptor
Alpha
Agonist

IRB# 16896
Study coming
soon
(relapsed/
refractory
MDS)

IRB# 16964
Study coming
soon

IRB# 16896
Study coming
soon

IRB# 15993
Study coming
soon

Myelodysplastic Syndrome (MDS)

Intermediate and
High Risk

Untreated
MDS

IRB#16867
Study coming
soon
(treatment	naïve high
risk MDS)

IRB#15619
Phase 1/2
Vadastuximab
Talirine (SGN-CD33A) plus
Standard of
care chemo in
intermediate
to high risk
MDS

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

Chronic Myelomonocytic Leukemia (CMML)

IDH1

4/13/17

http://www.ohsu.edu/research/nda/so/knight.php